- Home
- SWTX vs MRP Comparison
SWTX vs MRP Comparison
Compare SWTX & MRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- MRP
- Stock Information
- Founded
- SWTX 2017
- MRP N/A
- Country
- SWTX United States
- MRP United States
- Employees
- SWTX N/A
- MRP N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- MRP
- Sector
- SWTX Health Care
- MRP
- Exchange
- SWTX Nasdaq
- MRP NYSE
- Market Cap
- SWTX 3.5B
- MRP 4.1B
- IPO Year
- SWTX 2019
- MRP N/A
- Fundamental
- Price
- SWTX $47.00
- MRP $28.52
- Analyst Decision
- SWTX Buy
- MRP Strong Buy
- Analyst Count
- SWTX 7
- MRP 2
- Target Price
- SWTX $56.86
- MRP $30.75
- AVG Volume (30 Days)
- SWTX 4.5M
- MRP 962.1K
- Earning Date
- SWTX 08-06-2025
- MRP 08-18-2025
- Dividend Yield
- SWTX N/A
- MRP 9.09%
- EPS Growth
- SWTX N/A
- MRP N/A
- EPS
- SWTX N/A
- MRP N/A
- Revenue
- SWTX $219,670,000.00
- MRP $82,698,000.00
- Revenue This Year
- SWTX $74.36
- MRP N/A
- Revenue Next Year
- SWTX $75.63
- MRP N/A
- P/E Ratio
- SWTX N/A
- MRP N/A
- Revenue Growth
- SWTX 730.42
- MRP N/A
- 52 Week Low
- SWTX $28.21
- MRP $21.02
- 52 Week High
- SWTX $62.00
- MRP $28.99
- Technical
- Relative Strength Index (RSI)
- SWTX 63.86
- MRP N/A
- Support Level
- SWTX $46.93
- MRP N/A
- Resistance Level
- SWTX $47.02
- MRP N/A
- Average True Range (ATR)
- SWTX 0.08
- MRP 0.00
- MACD
- SWTX -0.06
- MRP 0.00
- Stochastic Oscillator
- SWTX 90.32
- MRP 0.00
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
About MRP MILLROSE PROPERTIES INC.
Millrose Properties Inc is a Holding Company. The company along with its subsidiaries engages in providing operational and capital solutions for home builders and land development companies to finance the acquisition and development of land assets through its Homesite Option Purchase Platform.